Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance.
release_wjlnbpa4r5hnhlos3qyu5qx2gq
by
Jianglan Liu, Vito W. Rebecca, Andrew V. Kossenkov, Thomas Connelly, Qin Liu, Alexis Gutierrez, Min Xiao, Ling Li, Gao Zhang, Anastasia Samarkina, Delaine Zayasbazan, Jie Zhang (+36 others)
2021 Volume 81, Issue 20, canres.1496.2020
Abstract
Metastatic melanoma is challenging to clinically address. Although standard of care targeted therapy has high response rates in patients with BRAF-mutant melanoma, therapy relapse occurs in most cases. Intrinsically resistant melanoma cells drive therapy resistance and display molecular and biologic properties akin to neural crest-like stem cells (NCLSCs) including high invasiveness, plasticity and self-renewal capacity. The shared transcriptional programs and vulnerabilities between NCLSCs and cancer cells remains poorly understood. Here, we identify a developmental LPAR1-axis critical for NCLSC viability and melanoma cell survival. LPAR1 activity increased during progression and following acquisition of therapeutic resistance. Notably, genetic inhibition of LPAR1 potentiated BRAFi +/- MEKi efficacy and ablated melanoma migration and invasion. Our data defines LPAR1 as a new therapeutic target in melanoma and highlights the promise of dissecting stem cell-like pathways hijacked by tumor cells.
In text/plain
format
Archived Files and Locations
application/pdf 14.7 MB
file_wxl2z5sqofebxo4imrnorcvfbq
|
cancerres.aacrjournals.org (publisher) web.archive.org (webarchive) |
application/pdf 1.8 MB
file_brdp5tns2zavxckrtxgsg73vee
|
cancerres.aacrjournals.org (web) web.archive.org (webarchive) |
access all versions, variants, and formats of this works (eg, pre-prints)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar